StockData
Codexis, Inc. logo

Codexis, Inc. (CDXS) stock analysis

CDXSNasdaqIndustrial Organic ChemicalsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 5/3013% below fair value
$0.98−0.02 (-2.36%)

Close on Nov 11, 2026Market cap $106.92MP/E –Yield –

StockData Score

Prices as of Nov 11, 2026How the score works

Value1Growth2Performance1Health1Dividend0

Weak5 of 30 checks passed

Codexis passes 5 of the 30 checks behind our score; 14 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
1/6
Growth
2/6
Past performance
1/6
Financial health
1/6
Dividend
0/6

What stands out

  • Trading below fair value

    The share price of $0.98 is below our fair value estimate of $1.12.

  • Growing faster than the industry

    Revenue grew 35.9% over the last twelve months; the Chemicals and Allied Products median is 3.5%.

  • Gross margin improving

    Gross margin was 87.0% over the last twelve months, against 77.6% a year earlier.

  • Net margin above its 5-year average

    Net margin was -39.6% over the last twelve months, against a 5-year average of -65.1%.

What to watch

  • Margin of safety under 20%

    The price is 13.1% below fair value, less than the 20% cushion we look for.

  • Return on equity under 15%

    Return on equity was -69.4% over the last twelve months and averaged -52.0% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -91.8%, below the 10% that usually covers the cost of capital.

  • High debt

    Debt is 124% of shareholders' equity, above the 40% we consider low.

Valuation1/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/B above the industry

    Codexis's price-to-book of 3.24 is above the Chemicals and Allied Products median of 1.51.

  • Trading below fair value

    The share price of $0.98 is below our fair value estimate of $1.12.

  • Margin of safety under 20%

    The price is 13.1% below fair value, less than the 20% cushion we look for.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -20.2% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 35.9% over the last twelve months; the Chemicals and Allied Products median is 3.5%.

  • Guidance issued

    The latest outlook (full-year 2026 Total revenues, Aug 11, 2026) was issued for the first time, so it neither adds nor takes away points.

  • Gross margin improving

    Gross margin was 87.0% over the last twelve months, against 77.6% a year earlier.

Past performance1/6

  • Return on equity under 15%

    Return on equity was -69.4% over the last twelve months and averaged -52.0% over five years; we look for 15% on both.

  • Return on capital under 10%

    Return on invested capital was -91.8%, below the 10% that usually covers the cost of capital.

  • Return on equity below the industry

    Codexis's return on equity of -69.4% is below the Chemicals and Allied Products median of -16.2%.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -39.6% over the last twelve months, against a 5-year average of -65.1%.

  • Net margin below the industry

    Codexis's net margin of -39.6% is below the Chemicals and Allied Products median of -13.3%.

Financial health1/6

  • High debt

    Debt is 124% of shareholders' equity, above the 40% we consider low.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals -25.5% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets cover short-term debts

    Current assets are 3.06 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -6.21; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Codexis has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$1.12

The share price is 13% below this estimate.

20%+ below
Near fair value
20%+ above
$0.98Price$1.12Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/B2.4×3.3×1.5×$0.7350%
P/S2.1×3.1×1.2×$1.5250%
Fair value$1.12100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 3.3
  • Chemicals and Allied Products median 1.5

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$1.05M
Value traded per 1% price move
$321.61K

Downside

High risk

Typical loss in a bad month
40.1%
Volatility (annualized)
86%
Sharpe ratio, 1 year
-0.57
Beta to the S&P 500 (5Y)
2.40

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2011 to 2025

Gross margin

86.7%+6.6 pts over 5 years

Operating margin

-59.3%−24.7 pts over 5 years

Net margin

-62.5%−27.7 pts over 5 years

See a number that looks wrong?